Asset Details
Do you wish to reserve the book?
Proapoptotic Bcl-2 inhibitor as potential host directed therapy for pulmonary tuberculosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Proapoptotic Bcl-2 inhibitor as potential host directed therapy for pulmonary tuberculosis
Do you wish to request the book?
Proapoptotic Bcl-2 inhibitor as potential host directed therapy for pulmonary tuberculosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Proapoptotic Bcl-2 inhibitor as potential host directed therapy for pulmonary tuberculosis
2025
Overview
Mycobacterium tuberculosis
establishes within host cells by inducing anti-apoptotic Bcl-2 family proteins, triggering necrosis, inflammation, and fibrosis. Here, we demonstrate that navitoclax, an orally bioavailable, small-molecule Bcl-2 inhibitor, significantly improves pulmonary tuberculosis (TB) treatments as a host-directed therapy. Addition of navitoclax to standard TB treatments at human equipotent dosing in mouse models of TB, inhibits Bcl-2 expression, leading to improved bacterial clearance, reduced tissue necrosis, fibrosis and decreased extrapulmonary bacterial dissemination. Using immunohistochemistry and flow cytometry, we show that navitoclax induces apoptosis in several immune cells, including CD68
+
and CD11b
+
cells. Finally, positron emission tomography (PET) in
live
animals using clinically translatable biomarkers for apoptosis (
18
F-ICMT-11) and fibrosis (
18
F-FAPI-74), demonstrates that navitoclax significantly increases apoptosis and reduces fibrosis in pulmonary tissues, which are confirmed in postmortem analysis. Our studies suggest that proapoptotic drugs such as navitoclax can potentially improve pulmonary TB treatments, reduce lung damage / fibrosis and may be protective against post-TB lung disease.
Mycobacterium tuberculosis
prevents host-cell apoptosis, causing necrosis and fibrosis, leading to tissue damage. Singh et al. show that strategic targeting of apoptosis with Bcl-2 inhibitors may enhance TB treatments and be protective against post-TB lung disease.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 13/21
/ 13/31
/ 13/51
/ 14
/ 14/63
/ 59/78
/ 64
/ 64/60
/ Aniline Compounds - pharmacology
/ Aniline Compounds - therapeutic use
/ Animals
/ Antitubercular Agents - pharmacology
/ Antitubercular Agents - therapeutic use
/ Damage
/ Female
/ Fibrosis
/ Humanities and Social Sciences
/ Humans
/ Mice
/ Mycobacterium tuberculosis - drug effects
/ Necrosis
/ Positron emission tomography
/ Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors
/ Proto-Oncogene Proteins c-bcl-2 - metabolism
/ Science
/ Sulfonamides - therapeutic use
/ Tuberculosis, Pulmonary - diagnostic imaging
/ Tuberculosis, Pulmonary - drug therapy
